A Study of ZD1839 Effects on Cell Proliferation in Breast Cancer

NCT00252811 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Gefitinib

Sponsor

AstraZeneca